Bolt Biotherapeutics Inc
For the period ended Dec 31, 2023. Filed Mar 21, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 21, 2024
BOLT$6.43-1.7%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Balance Sheets
(in thousands, except share and per share amounts)
| December 31, | ||
|---|---|---|
| 2023 | 2022 | |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $10,810 | $9,244 |
| Short-term investments | 91,379 | 159,644 |
| Prepaid expenses and other current assets | 3,519 | 3,858 |
| Total current assets | 105,708 | 172,746 |
| Property and equipment, net | 4,957 | 6,453 |
| Operating lease right-of-use assets | 19,120 | 22,072 |
| Restricted cash | 1,765 | 1,565 |
| Long-term investments | 26,413 | 23,943 |
| Other assets | 1,821 | 1,028 |
| Total assets | $159,784 | $227,807 |
| Liabilities and stockholders' equity | ||
| Current liabilities: | ||
| Accounts payable | $2,987 | $3,594 |
| Accrued expenses and other current liabilities | 12,486 | 15,140 |
| Deferred revenue | 2,201 | 1,993 |
| Operating lease liabilities | 2,782 | 2,391 |
| Total current liabilities | 20,456 | 23,118 |
| Operating lease liabilities, net of current portion | 17,437 | 20,220 |
| Deferred revenue, non-current | 9,107 | 12,921 |
| Other long-term liabilities | 43 | 42 |
| Total liabilities | 47,043 | 56,301 |
| Commitments and contingencies (Note 7) | ||
| Stockholders' equity: | ||
| Preferred stock, $0.00001 par value, authorized shares—10,000,000 shares authorized at December 31, 2023 and 2022; zero shares issued and outstanding at December 31, 2023 and 2022 | — | — |
| Common stock, $0.00001 par value; 200,000,000 shares authorized at December 31, 2023 and 2022; 38,114,606 and 37,797,902 shares issued and outstanding at December 31, 2023 and 2022, respectively | 1 | — |
| Additional paid-in capital | 476,988 | 467,513 |
| Accumulated other comprehensive gain (loss) | 37 | (919) |
| Accumulated deficit | (364,285) | (295,088) |
| Total stockholders' equity | 112,741 | 171,506 |
| Total liabilities, convertible preferred stock, and stockholders' equity | $159,784 | $227,807 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.